18/12/2020 – AB Science communicates the results from phase 2B/3 study evaluating masitinib in Alzheimer’s disease Download PDF Post navigationPreviousPrevious post:Masitinib in Alzheimer’s Disease Webcast PresentationNextNext post:Capital raise for a total amount of 15 million eurosRelated PostsBoursorama interview of Alain Moussy, CEO of AB ScienceDecember 23, 2020Capital raise for a total amount of 15 million eurosDecember 21, 2020Masitinib in Alzheimer’s Disease Webcast PresentationDecember 17, 2020Results of the Extraordinary General Shareholders’ Meeting of December 16, 2020December 17, 2020Corrective press release regarding adverse events information from study AB09004December 17, 2020Live webcast on Thursday December 17, 2020 on masitinib’s results in Alzheimer’s DiseaseDecember 16, 2020
Live webcast on Thursday December 17, 2020 on masitinib’s results in Alzheimer’s DiseaseDecember 16, 2020
